AR071937A1 - Metodo y composicion para tratar hipertension ocular y glaucoma que comprende analogos de pgf-2alfa, uso y metodo para aumentar la solubilidad acuosa y mejorar la estabilidad de los analogos de pgf-2alfa - Google Patents

Metodo y composicion para tratar hipertension ocular y glaucoma que comprende analogos de pgf-2alfa, uso y metodo para aumentar la solubilidad acuosa y mejorar la estabilidad de los analogos de pgf-2alfa

Info

Publication number
AR071937A1
AR071937A1 ARP090101912A ARP090101912A AR071937A1 AR 071937 A1 AR071937 A1 AR 071937A1 AR P090101912 A ARP090101912 A AR P090101912A AR P090101912 A ARP090101912 A AR P090101912A AR 071937 A1 AR071937 A1 AR 071937A1
Authority
AR
Argentina
Prior art keywords
polyoxyethylene
oxyethylene
poly
aqueous solution
pluronic
Prior art date
Application number
ARP090101912A
Other languages
English (en)
Inventor
Timo Reunamaki
Pertti Pellinen
Olli Oksala
Kari Lehmussaari
Original Assignee
Santen Pharmaceutical Co Ltd
Asahi Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071937(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd, Asahi Glass Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of AR071937A1 publication Critical patent/AR071937A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Una solucion acuosa oft lmica para tratar la hipertension ocular y el glaucoma, caracterizado porque comprende an logos de PGF2alfa como un ingrediente activo, donde dicha solucion acuosa oft lmica contiene tensioactivo no ionico, agente estabilizante y sustancialmente sin conservantes en un envase que consiste esencialmente de polietileno. Reivindicacion 2: La solucion acuosa oft lmica de acuerdo con la reivindicacion 1 caracterizado porque el an logo de PGF2alfa se selecciona del grupo integrado por latanoprost, isopropil unoprostone, travoprost, bimatoprost y tafluprost o una mezcla de dos o m s de los mismos. Reivindicacion 5: La solucion acuosa oft lmica de acuerdo con cualquiera de las reivindicaciones 1 a 4 caracterizado porque el tensioactivo no ionico se selecciona del grupo integrado por esteres grasos de polioxietileno tales como polisorbato 80 [poli(oxietileno) sorbitan monooleato], polisorbato 60 [poli(oxietileno) sorbitan monoestearato], polisorbato 40 [poli (oxietileno) sorbitan monopalmitato], [poli (oxietileno) sorbitan monolaurato, [poli(oxietileno) sorbitan trioleato y polisorbato 65 [poli(oxietileno) sorbitan tristearato], aceites de ricino hidrogenados con polioxietileno tales como aceite de ricino hidrogenado con polioxietileno 10, aceite de ricino hidrogenado con polioxietileno 40, aceite de ricino hidrogenado con polioxietileno 50 y aceite de ricino hidrogenado con polioxietileno 60, polioxietilen polioxipropilen glicoles tales como polioxietileno (160) polioxipropileno (30) glicol [Pluronic F68], polioxietileno (42) polioxipropileno (67) glicol [Pluronic P123], polioxietileno (54) polioxipropileno (39) glicol [Pluronic P85], polioxietileno (196) polioxipropileno (67) glicol [Pluronic F127], y polioxietileno 20) polioxipropileno (20) glicol [Pluronic L-44], polioxil 40 estearato y esteres grasos de sacarosa. Reivindicacion 8: La solucion acuosa oft lmica de acuerdo con cualquiera de las reivindicaciones 1 a 7 caracterizado porque el agente estabilizante se selecciona del grupo integrado por  cido etilendiaminatetraacetico y sus sales, nitrito de sodio,  cido ascorbico, estearato de  cido L-ascorbico, hidrogenosulfito sodico, alfatioglicerina,  cido eritorbico, clorhidrato ciste¡na,  cido c¡trico, tocoferol acetato, dicloisocianurato pot sico, 2,6-di-t-butil-4-metilfenol, lecitina de soja, tioglicolato de sodio, tiomalato de sodio, vitamina E natural, tocoferol, ascorbil pastiminato, pirosulfito de sodio, butilhidroxianisol, 1,3-butilenglicol, pentaeritil tetrakis [3-(3,5-di-t-butil-4-hidroxifenil)]propionato, propil galato, 2-mercaptobencimidazol y oxiquinolina sulfato. Reivindicacion 12: La solucion acuosa oft lmica de acuerdo con cualquiera de las reivindicaciones 1 a 11 caracterizado porque comprende al menos una sustancia activa para uso farmaceutico, tal como timolol.
ARP090101912A 2008-05-30 2009-05-28 Metodo y composicion para tratar hipertension ocular y glaucoma que comprende analogos de pgf-2alfa, uso y metodo para aumentar la solubilidad acuosa y mejorar la estabilidad de los analogos de pgf-2alfa AR071937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
AR071937A1 true AR071937A1 (es) 2010-07-28

Family

ID=39940592

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090101912A AR071937A1 (es) 2008-05-30 2009-05-28 Metodo y composicion para tratar hipertension ocular y glaucoma que comprende analogos de pgf-2alfa, uso y metodo para aumentar la solubilidad acuosa y mejorar la estabilidad de los analogos de pgf-2alfa
ARP180103181A AR120961A2 (es) 2008-05-30 2018-11-01 Método y composición para tratar hipertensión ocular y glaucoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180103181A AR120961A2 (es) 2008-05-30 2018-11-01 Método y composición para tratar hipertensión ocular y glaucoma

Country Status (27)

Country Link
US (3) US9999593B2 (es)
EP (7) EP2127638A1 (es)
JP (9) JP2011521943A (es)
KR (5) KR102246598B1 (es)
CN (1) CN102083413B (es)
AR (2) AR071937A1 (es)
AU (1) AU2009252210C1 (es)
BR (1) BRPI0913109B8 (es)
CA (2) CA2965185A1 (es)
CY (2) CY1115565T1 (es)
DK (4) DK3205334T3 (es)
EA (1) EA023661B1 (es)
ES (5) ES2808050T3 (es)
GE (1) GEP20156220B (es)
HR (4) HRP20220361T1 (es)
HU (3) HUE049923T2 (es)
JO (1) JO3039B1 (es)
LT (3) LT3205334T (es)
MX (1) MX2010012987A (es)
MY (1) MY159463A (es)
PL (4) PL2772249T3 (es)
PT (4) PT3205334T (es)
SG (1) SG191628A1 (es)
SI (4) SI3714877T1 (es)
TW (1) TWI432202B (es)
UA (1) UA102257C2 (es)
WO (1) WO2009145356A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
KR101820184B1 (ko) 2010-07-29 2018-01-18 알러간, 인코포레이티드 방부제가 없는 비마토프로스트 및 티몰롤 용액
US20130245124A1 (en) * 2010-07-29 2013-09-19 Allergan, Inc. Preservative free bimatoprost solutions
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
WO2012038469A2 (en) 2010-09-21 2012-03-29 S&V Technologies Ag Cosmetic composition
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
KR20140038404A (ko) * 2011-04-12 2014-03-28 가부시키가이샤 아루떼꾸 우에노 수성 안과용 조성물
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
EP2887923B1 (en) * 2012-08-24 2023-04-05 Sun Pharmaceutical Industries Limited Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
EP3091985B1 (en) 2014-01-10 2024-05-08 Manistee Therapeutics, Inc. Prostanglandins for topical use in the treatment of migraines.
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
ES2747302T3 (es) 2015-06-09 2020-03-10 Medproject Pharma Entw Und Vertriebsgesellschaft Mbh Gel oftálmico de bimatoprost aplicable en gotas
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
CN108883081A (zh) * 2015-11-06 2018-11-23 阿克西制药有限公司 蛋白酶体抑制剂治疗眼部疾病的用途
EP4364810A3 (en) 2015-11-10 2024-07-24 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
PT3423076T (pt) 2016-02-29 2024-07-01 Sun Pharmaceutical Ind Ltd Formulações tópicas contendo ciclosporina e respetivas utilizações
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
EP3603642B1 (en) * 2017-03-27 2024-01-10 Alcon Inc. Pharmaceutical preparation
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
EP3643297A4 (en) 2017-06-22 2021-03-17 Yonsung Fine Chemical Co., Ltd. OPHTHALMIC COMPOSITION FOR GLUCOMA TREATMENT
TWI833535B (zh) * 2017-12-21 2024-02-21 日商參天製藥股份有限公司 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥
CA3104060A1 (en) 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Ophthalmic dispensing device
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
WO2023182480A1 (ja) * 2022-03-25 2023-09-28 株式会社坪田ラボ 水性組成物
WO2023241652A1 (zh) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
ES2042625T5 (es) 1987-04-03 2000-07-16 Univ Columbia Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
EP0861079A1 (en) * 1995-11-17 1998-09-02 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
EP0930296B2 (en) 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorinated prostaglandin derivatives and medicines
EP0944530A1 (en) 1996-12-09 1999-09-29 Bausch & Lomb Incorporated Single-use flexible container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
DK0979652T3 (da) * 1997-10-13 2006-09-11 R Tech Ueno Ltd Helbredende præparat til intraokulær hypertension eller glaukom
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
EP1011728B1 (en) 1998-07-14 2004-12-29 Alcon Manufacturing, Ltd. Polypropylene containers for prostaglandin products
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
EP1115406A4 (en) 1998-09-25 2003-03-05 Alcon Lab Inc SUSTAINABLE RELEASE OPHTHALMIC COMPOSITION AND METHOD OF EYE THERAPY
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
ES2305606T3 (es) 1999-04-06 2008-11-01 Sepracor Inc. Succinato de o-desmetilvenlafaxina.
KR100791871B1 (ko) 2000-06-19 2008-01-07 산텐 세이야꾸 가부시키가이샤 방부제
ES2357551T3 (es) 2000-09-13 2011-04-27 Santen Pharmaceutical Co., Ltd. Colirio.
JP3876355B2 (ja) 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
WO2004006826A1 (ja) 2002-07-16 2004-01-22 Senju Pharmaceutical Co., Ltd. 薬液容器及びその製造方法
KR20050057251A (ko) 2002-09-09 2005-06-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
WO2005011704A1 (ja) * 2003-07-31 2005-02-10 Santen Pharmaceutical Co., Ltd. プロスタグランジン含有製品
US20050287325A1 (en) 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
EP1655021B1 (en) * 2004-11-09 2008-10-29 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
WO2006058139A2 (en) 2004-11-24 2006-06-01 Holopack International Corp. Dispensing container with flow control system
JP2006187602A (ja) 2004-12-09 2006-07-20 Santen Pharmaceut Co Ltd 分子内にフッ素原子を有するプロスタグランジン含有製品
SI1829545T1 (sl) * 2004-12-24 2012-08-31 Santen Pharmaceutical Co Ltd Produkti, vsebujoči prostaglandin F2 alfa derivat
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
ES2393675T3 (es) 2005-07-13 2012-12-27 Santen Pharmaceutical Co., Ltd. Composición conservante para uso oftálmico
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
ATE479424T1 (de) 2005-10-10 2010-09-15 Novagali Pharma Sa Prostaglandine enthaltende ophthalmische emulsionen
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
BRPI0913109A2 (pt) 2017-06-20
KR20190067272A (ko) 2019-06-14
TW201000104A (en) 2010-01-01
LT2772249T (lt) 2017-09-11
US9999593B2 (en) 2018-06-19
HRP20140979T1 (hr) 2014-11-21
JP7265584B2 (ja) 2023-04-26
GEP20156220B (en) 2015-01-26
AU2009252210A1 (en) 2009-12-03
PT2306977E (pt) 2014-09-22
EP4035656A1 (en) 2022-08-03
HUE058079T2 (hu) 2022-06-28
LT3714877T (lt) 2022-04-11
JO3039B1 (ar) 2016-09-05
TWI432202B (zh) 2014-04-01
AU2009252210C1 (en) 2016-04-14
KR102246598B1 (ko) 2021-04-30
KR101650006B1 (ko) 2016-08-22
BRPI0913109B1 (pt) 2019-10-22
MY159463A (en) 2017-01-13
JP6889789B2 (ja) 2021-06-18
AR120961A2 (es) 2022-04-06
EP2306977B1 (en) 2014-08-13
ES2968837T3 (es) 2024-05-14
KR20160102319A (ko) 2016-08-29
SG191628A1 (en) 2013-07-31
CN102083413B (zh) 2013-11-06
DK2306977T3 (da) 2014-09-15
JP2014133765A (ja) 2014-07-24
LT3205334T (lt) 2020-09-25
ES2627837T8 (es) 2018-02-26
SI3714877T1 (sl) 2022-05-31
EP4289446A3 (en) 2024-01-10
HRP20220361T1 (hr) 2022-05-13
JP2018154656A (ja) 2018-10-04
PL3714877T3 (pl) 2022-05-16
PL2306977T3 (pl) 2015-01-30
JP2016065095A (ja) 2016-04-28
JP7520285B2 (ja) 2024-07-23
ES2808050T3 (es) 2021-02-25
CY1115565T1 (el) 2017-01-04
US10864159B2 (en) 2020-12-15
EP2306977A1 (en) 2011-04-13
JP6148317B2 (ja) 2017-06-14
US20110152264A1 (en) 2011-06-23
MX2010012987A (es) 2011-02-24
EP2772249A1 (en) 2014-09-03
KR20110011707A (ko) 2011-02-08
JP6356868B2 (ja) 2018-07-11
CY1120351T1 (el) 2019-07-10
EP3205334A1 (en) 2017-08-16
CN102083413A (zh) 2011-06-01
ES2495316T3 (es) 2014-09-17
UA102257C2 (uk) 2013-06-25
PT3205334T (pt) 2020-07-31
JP2024079852A (ja) 2024-06-11
HUE049923T2 (hu) 2020-11-30
HRP20170769T1 (hr) 2017-08-11
DK3714877T3 (da) 2022-02-14
US20210059931A1 (en) 2021-03-04
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
SI2772249T1 (sl) 2017-08-31
US20180289618A1 (en) 2018-10-11
EA201071413A1 (ru) 2011-06-30
EP2127638A1 (en) 2009-12-02
DK3205334T3 (da) 2020-07-13
EP2772249B1 (en) 2017-05-03
HRP20200998T1 (hr) 2020-10-16
EP3714877B1 (en) 2022-01-26
BRPI0913109B8 (pt) 2021-05-25
ES2907982T3 (es) 2022-04-27
JP6649992B2 (ja) 2020-02-19
EA023661B1 (ru) 2016-06-30
CA2724194A1 (en) 2009-12-03
KR20180008905A (ko) 2018-01-24
PL3205334T3 (pl) 2020-11-02
PT3714877T (pt) 2022-03-10
KR102114401B1 (ko) 2020-05-25
KR101988642B1 (ko) 2019-06-12
EP4035656B1 (en) 2023-11-22
JP2011521943A (ja) 2011-07-28
HUE033103T2 (en) 2017-11-28
DK2772249T3 (en) 2017-07-17
EP3714877A1 (en) 2020-09-30
CA2724194C (en) 2017-06-27
PL2772249T3 (pl) 2017-10-31
CA2965185A1 (en) 2009-12-03
KR20200057801A (ko) 2020-05-26
EP3205334B1 (en) 2020-04-29
PT2772249T (pt) 2017-08-08
JP2023085558A (ja) 2023-06-20
JP2017178957A (ja) 2017-10-05
KR101820816B1 (ko) 2018-01-22
EP4289446A2 (en) 2023-12-13
JP2021120412A (ja) 2021-08-19
ES2627837T3 (es) 2017-07-31
JP2020073574A (ja) 2020-05-14
AU2009252210B2 (en) 2014-10-16
WO2009145356A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
AR071937A1 (es) Metodo y composicion para tratar hipertension ocular y glaucoma que comprende analogos de pgf-2alfa, uso y metodo para aumentar la solubilidad acuosa y mejorar la estabilidad de los analogos de pgf-2alfa
JP2016065095A5 (es)
ES2357551T3 (es) Colirio.
CN105899209B (zh) 含有吡啶基氨基乙酸化合物的药物制剂
KR102675685B1 (ko) 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
RU2010139958A (ru) Стабилизированная фармацевтическая композиция, cодержащая доцетаксель
RU2011146005A (ru) Композиции для лечения воспаления и способы лечения воспаления
MX2012012846A (es) Composicion oftalmica.
CA2498233A1 (en) Clear ophthalmic solution comprising latanoprost as active ingredient
RU2013126259A (ru) Фармацевтическая композиция таксоидов
JP6185725B2 (ja) 水性医薬組成物
RU2011150246A (ru) Эмульсия "масло-в-воде" моментазона и пропиленгликоля
JP5582768B2 (ja) 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物
NZ596035A (en) METHOD AND COMPOSITION FOR TREATING MACULAR DEGENERATION using 15-keto-prostaglandin such as 13,14-dihydro-15-keto-20-ethyl-prostagladin F2-alpha isopropyl ester
CN106999452A (zh) 前列腺素类和一氧化氮供体的组合产品
KR20120095341A (ko) 라타노프로스트의 생체 이용율의 개선 방법

Legal Events

Date Code Title Description
FC Refusal